Among the participants whose CSF was analyzed but not all biomarkers were abnormal, a considerable proportion had CSF p-tau within the normal range and an A+T−N+ profile, indicating either subthreshold tauopathy or amyloidosis in combination with non-AD pathologies [27–29]. The gene discussed is MAPT; the disease is tauopathy.